02474nas a2200385 4500000000100000008004100001260001600042653001500058653001000073653000900083653002200092653002500114653001100139653001300150653001100163653001200174653000900186653002700195653001600222653002600238100002300264700001200287700002000299700001400319700001600333700002200349700001600371700001300387245012400400856010800524300001200632490000800644520142200652022001402074 2007 d c2007 Nov 0110aAdolescent10aAdult10aAged10aAged, 80 and over10aCase-Control Studies10aFemale10agenotype10aHumans10aleprosy10aMale10aMannose-Binding Lectin10aMiddle Aged10aPolymorphism, Genetic1 aMessias-Reason LJT1 aBoldt A1 aMoraes Braga AC1 aStahlke E1 aDornelles L1 aPereira-Ferrari L1 aKremsner PG1 aKun JF J00aThe association between mannan-binding lectin gene polymorphism and clinical leprosy: new insight into an old paradigm. uhttp://jid.oxfordjournals.org/content/196/9/1379.full.pdf+html?sid=64d8458a-d31d-4e85-a05a-5e5d1a69b0d4 a1379-850 v1963 a

BACKGROUND: Mannan-binding lectin (MBL), a soluble protein of innate immunity, is known to play a role in pathogen recognition and clearance. For more than a decade, it has been proposed that MBL deficiency may be protective against intracellular pathogens, such as Mycobacterium leprae.

METHODS: The polymorphisms at the promoter and exon 1 regions of the MBL2 gene were assessed by polymerase chain reaction and sequencing performed on 264 patients with leprosy and 214 matched healthy control subjects from southern Brazil. RESULTS. The distribution of MBL2-gene polymorphisms in patients was significantly different from that in controls, with a decreased frequency of haplotypes/genotypes associated with low expression of circulating MBL in lepromatous patients when compared with tuberculoid patients (odds ratio [OR] for haplotypes, 0.56 [95% confidence interval {CI}, 0.33-0.93] [P=.020]; OR for genotypes, 0.31 [95% CI, 0.13-0.71] [P=.004]). The LYPA haplotype was associated with susceptibility to leprosy per se (OR, 2.25 [95% CI, 1.31-3.88] [P=.003]) and to progression to the lepromatous (OR, 2.2 [95% CI, 1.21-4.05] [P=.008]) and borderline (OR, 2.98 [95% CI, 1.29-6.87] [P=.008]) forms of the disease.

CONCLUSIONS: These results suggest that MBL2-gene polymorphisms play a role in susceptibility to leprosy per se and in the clinical progression of the disease.

 a0022-1899